Stocks and Investing Stocks and Investing
Thu, April 25, 2024

Joseph Catanzaro Maintained (ACRV) at Buy with Increased Target to $30 on, Apr 25th, 2024


Published on 2024-10-28 10:39:03 - WOPRAI, Joseph Catanzaro
  Print publication without navigation


Joseph Catanzaro of Piper Sandler, Maintained "Acrivon Therapeutics, Inc." (ACRV) at Buy with Increased Target from $26 to $30 on, Apr 25th, 2024.

Joseph has made no other calls on ACRV in the last 4 months.



There are 2 other peers that have a rating on ACRV. Out of the 2 peers that are also analyzing ACRV, 0 agree with Joseph's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Joseph


  • Aydin Huseynov of "Ladenburg Thalmann" Maintained at Strong Buy with Decreased Target to $14 on, Friday, April 5th, 2024
  • Etzer Darout of "BMO Capital" Reiterated at Buy and Held Target at $18 on, Monday, April 1st, 2024
Contributing Sources